The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies.
Hum Antibodies
; 25(3-4): 111-119, 2017.
Article
en En
| MEDLINE
| ID: mdl-28035916
ABSTRACT
One of the most exciting fields in modern medicine is immunotherapy, treatment which looks to harness the power of the immune system to fight disease. A particularly effective strategy uses antibodies designed to influence the activity levels of the immune system. Here we look at two receptors - TIGIT and DNAM-1 - which bind the same ligands but have opposite effects on immune cells, earning them the label `paired receptors'. Importantly, natural killer cells and cytotoxic T cells express both of these receptors, and in certain cases their effector functions are dictated by TIGIT or DNAM-1 signaling. Agonist and antagonist antibodies targeting either TIGIT or DNAM-1 present many therapeutic options for diseases spanning from cancer to auto-immunity. In this review we present cases in which the modulation of these receptors holds potential for the development of novel therapies.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Enfermedades Autoinmunes
/
Receptores Inmunológicos
/
Antígenos de Diferenciación de Linfocitos T
/
Antineoplásicos Inmunológicos
/
Inmunoterapia
/
Neoplasias
Límite:
Humans
Idioma:
En
Revista:
Hum Antibodies
Asunto de la revista:
ALERGIA E IMUNOLOGIA
Año:
2017
Tipo del documento:
Article